Product Datasheet

Recombinant Human Insulin-like Growth Factor-Binding Protein 3

Catalog No: #AP60064




Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Package Size: #AP60064-1 5ug #AP60064-2 100ug #AP60064-3 500ug

Description	
Product Name	Recombinant Human Insulin-like Growth Factor-Binding Protein 3
Host Species	Escherichia coli.
Purification	> 98 % by SDS-PAGE and HPLC analyses.
Other Names	Growth-hormone-dependant Binding Protein, IBP-3, IGF-binding protein 3
Uniprot	P17936
GenelD	3486
Calculated MW	Approximately 28.8 kDa, a single non-glycosylated polypeptide chain containing 264 amino acids.
Target Sequence	GASSAGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER
	CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG
	SVESPSVSST HRVSDPKFHP LHSKIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM
	EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT
	KGKEDVHCYS MQSK
Formulation	Lyophilized from a 0.2 μ m filtered concentrated solution in PBS, pH 7.4.
Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles 12 months from date of receipt, -20 to
	-70 °C as supplied 1 month, 2 to 8 °C under sterile conditions after reconstitution 3 months, -20 to -70 °C
	under sterile conditions after reconstitution.

Images



Background

Insulin-like Growth Factor-Binding Protein 3 (IGF-BP3) belongs to the IGFBP family, which are all cysteinerich proteins with conserved cysteine and have an IGFBP domain and a thyroglobulin type-I domain. Mature human IGF-BP3 contains 264 a.a. with three potential N-linked and two potential O-linked glycosylation sites. It is expressed by most tissues and has higher levels during extrauterine life and peak during puberty. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. The protein forms a ternary complex with IGF-I or II and acid-labile subunit. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Decreased plasma levels of IGF-BP3 often happen during the progression of prostate cancer from benign to metastatic

Note: This product is for in vitro research use only